Recipharm and Astimex Pharma form new development and manufacturing collaboration

Recipharm AB and Astimex Pharma AB have today announced the formation of a collaboration agreement for the development and manufacture of a pharmaceutical product. The formulation development work will take place at the Recipharm Pharmaceutical Development site located in Solna close to Stockholm. Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product.

Additionally, Astimex is in discussions with Recipharm for engagement to carry out other manufacturing and development contractual projects. 
Maria Lundberg, General Manager, Recipharm Pharmaceutical Development commented: "I am convinced that this is the start of a long-term collaboration that will prove beneficial for both companies and we are pleased that Astimex Pharma have chosen to utilise the expertise and flexible development capabilities that our staff and facilities are able to provide."

Åsa Lintzen, General Manager, Astimex Pharma AB, said: "We are delighted to be working closely with Recipharm on this specific manufacturing and development project. Indeed, it is Recipharm's recognised partnering approach, combined with its advanced and adaptable capabilities, including its offering at the Solna facility that attracted us in the first place." 

She added: "Moreover, we were looking for a CDMO that we could build a long term relationship with and consequently we are already exploring the scope for working with  Recipharm on other  projects."    

Notes to editors
About Recipharm
Recipharm AB is a leading contract development and manufacturing organization (CDMO) based in Sweden employing some 1700 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers.

Recipharm's Pharmaceutical Development Services group offer services from straight forward manufacture of clinical trial material through to more complex product development and formulation. From our pharmaceutical development centre we can work on a variety of technologies, including sterile products. Formulation development, analytical method development and stability studies are all core activities.
For more information visit;

About Astimex Pharma
Astimex Pharma is a Swedish pharmaceutical company founded in 2007. The company markets and distributes pharmaceuticals, medical devices and merchandise to the pharmacy market in Sweden, Denmark and Finland. Astimex has it´s headquarter near Stockholm.
Astimex ambition is to play an important role in the Nordic market by delivering products that are unique, effective, safe, environment friendly, user friendly and cost effective.
Astimex range is selected to improve the health and quality of life for consumers and patients.
The majority of revenues come from products sold under licensing or distribution agreements.
Astimex collaborating with leading contract development and manufacturing organizations.
For more information visit;

Contact information
Recipharm – Maria Lundberg, General Manager, +46 8 602 52 73
Astimex Pharma – Åsa Lintzén, General Manager, + 46 703 071313
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: [email protected] or [email protected]

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.